Skip to main content
YUNGJIN PHARM. CO., LTD logo

YUNGJIN PHARM. CO., LTD — Investor Relations & Filings

Ticker · 003520 ISIN · KR7003520004 KO Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2024-03-20 Annual Report
Country KR South Korea
Listing KO 003520

About YUNGJIN PHARM. CO., LTD

https://eng.yungjin.co.kr/

Yungjin Pharm. Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products for domestic and international markets. The company's portfolio includes a range of prescription drugs, with a focus on areas such as cephalosporin antibiotics and antipsychotic medications. Yungjin Pharm is actively involved in advancing its R&D pipeline, which includes collaborative research for treatments of rare conditions like mitochondrial diseases. Leveraging extensive drug production expertise and R&D capabilities, the company operates as a key affiliate within the KT&G Group's bio/pharmaceutical business.

Recent filings

Filing Released Lang Actions
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 62nd fiscal year (2023) of Yungjin Pharm. Co., Ltd. It contains comprehensive financial statements, management discussion and analysis, governance information, and operational details. It is a full-year statutory filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). According to the provided definitions, this corresponds to an Annual Report (10-K). FY 2023
2024-03-20 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Yungjin Pharm. It contains the agenda for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. It also includes detailed management information, such as board activity reports, governance details, and financial summaries, which are standard components of proxy materials sent to shareholders to solicit votes for an AGM. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2024-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often referred to as a Proxy Solicitation Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the agenda, voting procedures, and proxy solicitation details. While it includes financial statements, these are provided as reference materials for the shareholders' meeting rather than being the primary Annual Report (10-K) or an independent Audit Report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2024-03-13 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Youngjin Pharm. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and audit committee members). This type of document is sent to shareholders to provide information and request their participation/votes for the upcoming meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2024-03-05 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a short regulatory filing (1483 characters) titled '감사보고서 제출' (Submission of Audit Report). It provides a summary table of financial data and audit opinions for the fiscal year 2023, as required by Korean regulatory standards. Following the 'Menu vs Meal' rule, this is an announcement of the audit report's submission rather than the full audit report document itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2023
2024-03-04 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Regulatory Filings Classification · 95% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Youngjin Pharm, a subsidiary of the KT&G corporate group. It provides specific regulatory disclosures regarding group status, circular shareholding, voting rights, and inter-company transactions as required by Korean fair trade regulations. Since it is a regulatory disclosure document that does not fit into specific categories like financial reports or shareholder meeting materials, it falls under the general regulatory filing category.
2024-02-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.